Division of Neurology
Dr. Trudell is interested in the role of the microbiome in chronic diseases including Alzheimer's, Parkinson's, ALS (Lou Gehrig's Disease) and spondyloarthropathies. These data could lead to new insights into how our microbiome influences the immune system and whether immunomodulatory medications may work best for these conditions.
University of Rochester School of Medicine, Rochester, New York, 1979
Neurology, Strong Memorial Hospital, Rochester, NY, 1983
Neuromuscular Disease, Strong Memorial Hospital, Rochester, NY, 1985
American Academy of Neurology
Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, Maragakis NJ, McDermott CJ, Pestronk A, Ravits J, Salachas F, Trudell R, Van Damme P, Zinman L, Bennett CF, Lane R, Sandrock A, Runz H, Graham D, Houshyar H, McCampbell A, Nestorov I, Chang I, McNeill M, Fanning L, Fradette S, Ferguson TA.
Phase 1-2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. The New England Journal of Medicine. 2020 Jul 9;383(2):109-119.
Zivadinov R, Bergsland N, Korn JR, Dwyer MG, Khan N, Medin J, Price JC, Weinstock-Guttman B, Silva D, Ramasamy DP, Carl E, Hunter S, Scott T, Pandey K, Fox E, Katz A, Silversteen J, Kaplan J, Maa E, Simnad V, Shin R, Newman S, Kinkel P, Green B, Calkwood .
Feasibility of brain atrophy measurement in clinical routine without prior standardization of the MRI protocol: Results from MS-MRIUS, a longitudinal observational, multicenter real-world Outcome study in patients with relapsing-remitting MS. American Journal of Neuroradiology. 2018 Feb;39(2):289-295. Epub 2017 Nov 23.
The University of Tennessee Graduate School of Medicine
1924 Alcoa Highway
Knoxville, Tennessee 37920 | 865-305-9290
Copyright © 2019